Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) is a clinical-stage biopharmaceutical company whose news flow centers on the development of sabirnetug (ACU193), a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs) for the treatment of early Alzheimer’s disease. Company updates consistently highlight progress in its Phase 2 ALTITUDE-AD trial, scientific presentations, collaborations and financial disclosures.
Visitors to this ABOS news page can review press releases on key clinical milestones, such as enrollment updates and the initiation of the open-label extension portion of ALTITUDE-AD, as well as data readouts from the Phase 1 INTERCEPT-AD study and subsequent analyses. Acumen also reports on operational innovations in trial execution, including the use of a plasma pTau217 assay to streamline screening and reduce costs in its Phase 2 program.
In addition to clinical trial developments, Acumen regularly announces scientific findings presented at major Alzheimer’s and neurology conferences. These items include data on sabirnetug’s selectivity for AβOs over monomeric amyloid beta, biomarker results, and research on Enhanced Brain Delivery (EBD™) approaches in collaboration with JCR Pharmaceuticals using transferrin-receptor-targeting, blood–brain barrier-penetrating technology.
Investors and followers of ABOS will also find news related to corporate events, such as board appointments, strategic collaboration agreements and quarterly financial results, which are often accompanied by conference call and webcast details. This page provides a centralized view of Acumen’s public communications as it advances its AβO-targeted therapeutic programs for Alzheimer’s disease.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported financial results for Q2 2022, revealing a cash balance of $209.9 million as of June 30, anticipated to fund operations until 2025. The ongoing INTERCEPT-AD Phase 1 trial for ACU193 aims to deliver topline results in H1 2023, with 15 active clinical sites currently enrolling patients. R&D expenses surged to $7.3 million, reflecting increased clinical trial costs. Net loss decreased to $10.2 million compared to $61.4 million a year prior, influenced by significant prior year non-cash expenses.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will announce its Q2 2022 financial results on August 15, 2022, followed by a conference call at 4:30 p.m. ET. The company focuses on novel therapies for Alzheimer’s disease and is advancing its investigational drug, ACU193, in a Phase I clinical trial. Acumen has established itself in the biopharmaceutical sector, targeting the toxic Aβ oligomers linked to Alzheimer’s pathology. The audio from the call will be accessible via their website, with an archived version available for 30 days.
Acumen Pharmaceuticals has developed a synthetic model for soluble amyloid beta oligomers (AβOs), crucial for Alzheimer’s disease research. This model aims to standardize assays for AβOs, which have been challenging to study due to their complexity. The methodology will be presented at the Alzheimer’s Association International Conference (AAIC) from July 31 to August 4, 2022. The ongoing Phase 1 clinical trial of ACU193, targeting toxic AβOs, is expected to yield important data to advance Alzheimer’s research.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) announced its participation in two upcoming major conferences focusing on Alzheimer's disease. At the Alzheimer’s Association International Conference (AAIC) in San Diego, the company will present a poster on August 3, 2022, detailing their research on amyloid beta oligomers. Additionally, Dr. Eric Siemers, Chief Medical Officer, will speak at the BTIG Biotech Conference on August 8, 2022, discussing next-generation therapeutics targeting Alzheimer's pathology. Acumen is advancing its investigational product ACU193, a monoclonal antibody in Phase 1 trials.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported its Q1 2022 financial results, highlighting a cash balance of $216.7 million as of March 31, 2022, sufficient to fund operations through 2025. The company is advancing its Phase 1 clinical trial, INTERCEPT-AD, for its drug ACU193 targeting early Alzheimer’s disease, with topline data expected in the first half of 2023. R&D expenses increased to $6.0 million from $2.6 million YoY, reflecting ongoing trial costs. Acumen's net loss for the quarter was $9.1 million, a decrease from $27.0 million in Q1 2021.
Acumen Pharmaceuticals (NASDAQ: ABOS) will announce its Q1 2022 financial results on May 16, 2022, at 4:30 PM ET. The company will host a conference call and a live audio webcast to discuss business performance and financial updates. Acumen is focused on developing a novel therapy for Alzheimer’s disease, specifically targeting toxic AβOs through its investigational drug, ACU193, currently in Phase I trials. Interested investors can access the live webcast via the company’s website.
Acumen Pharmaceuticals (NASDAQ: ABOS) announces publication in Frontiers in Neuroscience of preclinical evidence supporting ACU193, a monoclonal antibody targeting amyloid beta oligomers for early Alzheimer's disease treatment. The publication indicates that AβO-mediated neuronal toxicity contributes to cognitive impairments in Alzheimer's patients. Key findings include ACU193's selectivity towards AβOs without binding to plaques, suggesting a reduced risk of amyloid-related imaging abnormalities. Ongoing Phase I clinical trials aim to validate these findings and explore ACU193's therapeutic potential.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported progress on ACU193, its monoclonal antibody targeting toxic amyloid-beta oligomers, currently in Phase 1 clinical trial INTERCEPT-AD for early Alzheimer's patients. The trial has experienced slower enrollment due to COVID-19, but topline results are expected in H1 2023. Acumen ended 2021 with $225.9 million in cash, sufficient to fund operations through 2025. The company's leadership was strengthened with new appointments, including Kim Drapkin to the Board. Net losses were $100.6 million in 2021, primarily due to non-cash expenses related to fair value changes.
Acumen Pharmaceuticals (ABOS) will report its financial results for Q4 and full year 2021 on March 28, 2022, at 4:30 PM ET. The company is focused on developing targeted therapeutics for Alzheimer’s disease, particularly its investigational drug ACU193, an immunotherapy targeting toxic AβOs, currently in a Phase I clinical trial. This conference call will update stakeholders on business and financial matters, with access available via the company’s website.
Acumen Pharmaceuticals, focusing on Alzheimer’s disease therapeutics, achieved a significant milestone by enrolling the first patients in the INTERCEPT-AD Phase 1 clinical trial for its investigational drug, ACU193. This humanized monoclonal antibody selectively targets toxic amyloid-beta oligomers (AβOs). Despite delays attributed to the COVID-19 Delta variant, Acumen expects to report topline data by the end of 2022. The company reported a net loss of $92.3 million for the nine-month period ending September 30, 2021, with cash and cash equivalents totaling $135.8 million.